Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6
- PMID: 29541391
- PMCID: PMC5834280
- DOI: 10.18632/oncotarget.23743
Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6
Erratum in
-
Correction: Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6.Oncotarget. 2018 Sep 28;9(76):34449. doi: 10.18632/oncotarget.26205. eCollection 2018 Sep 28. Oncotarget. 2018. PMID: 30344953 Free PMC article.
Abstract
We describe the clinical, morphologic, immunophenotypic and molecular genetic features of 15 cases of acute myeloid leukemia (AML) with t(4;12)(q12;p13). There were 9 men and 6 women, with a median age of 50 years (range, 17-76). Most patients had hypercellular bone marrow with a median blast count of 58% and multilineage dysplasia. Flow cytometry analysis showed myeloid lineage with blasts positive for CD13, CD33, CD34, CD38, CD117 and HLA-DR. Interestingly, aberrant CD7 expression was detected in 12/14 cases, and myeloperoxidase was either negative (3/15) or positive in only a small subset of the blasts (12/15). t(4;12)(q12;p13) was detected at time of initial diagnosis in 4 and at relapse or progression in 9 patients. The initial karyotype was unknown in 2 cases. FISH analysis showed PDGFRA-ETV6 rearrangement in all 7 cases assessed. FLT3 ITD was detected in 2/11 cases and IDH2 and JAK2 mutation were each detected in 1/2 cases assessed. There were no mutations of KRAS (0/8), NRAS (0/8), CEBPA (0/3), KIT (0/3), NPM1 (0/3) or IDH1 (0/2). All patients received aggressive multiagent chemotherapy; 7 patients additionally received stem cell transplantation. With a median follow-up of 10 months (range, 6-51), 13 patients died of AML, 1 patient had persistent disease, and 1 patient was lost to follow-up. In summary, AML with t(4;12)(q12;p13) is usually associated with myelodysplasia, aberrant CD7 expression, weak of absent myeloperoxidase expression, frequent PDGFRA-ETV6 fusion, and an aggressive clinical course. The molecular findings suggest that there may be a role for tyrosine kinase inhibitors in patient management.
Keywords: ETV6; PDGFRA; acute myeloid leukemia; t(4;12)(q12;p13).
Conflict of interest statement
CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Figures


References
-
- Harada H, Asou H, Kyo T, Asaoku H, Iwato K, Dohy H, Oda K, Harada Y, Kita K, Kamada N. A specific chromosome abnormality of t(4;12) (q11-12;p13) in CD7+ acute leukemia. Br J Haematol. 1995;90:850–4. - PubMed
-
- Cools J, Bilhou-Nabera C, Wlodarska I, Cabrol C, Talmant P, Bernard P, Hagemeijer A, Marynen P. Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukemias with a t(4;12) (q11-q12;p13) Blood. 1999;94:1820–4. - PubMed
-
- Den Nijs van Weert JI, Beverstock GC, Kievits T, Haak HL, Havik-Boggard FC, Leeksma CH. Der(1) (t(1;9): A specific chromosome abnormality in polycythemia vera? Cytogenetic and in situ hybridization studies. Cancer Genet Cytogenet. 1989;40:121–7. - PubMed
-
- Harada H, Harada Y, Eguchi M, Dohy H, Kamada N. Characterization of acute leukemia with t(4;12) Leuk Lymphoma. 1997;25:47–53. - PubMed
-
- Sainty D, Arnoulet C, Mozziconacci MJ, De Pina JJ, Garnotel E, Lafage-Pochitaloff M. t(4;12) (q11;p13) in a CD7-negative acute myeloid leukaemia. Br J Haematol. 1997;96:210–2. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources